Loading…
Loading…
The Invesco Nasdaq Biotechnology ETF (IBBQ) carries a lower expense ratio than the iShares Global Healthcare ETF (IXJ). IXJ offers broad global exposure across the healthcare sector, while IBBQ is concentrated exclusively in Nasdaq-listed biotechnology and pharmaceutical companies.
State Street Health Care Select Sector SPDR ETF offers a lower expense ratio and a higher dividend yield than Invesco Nasdaq Biotechnology ETF Invesco Nasdaq Biotechnology ETF provides concentrated exposure to the biotech industry but has experienced higher volatility and a deeper maximum drawdown State Street Health Care Select Sector SPDR ETF tracks a broader index of 60 healthcare stocks from the S&P 500 compared to the Invesco fund's 253 biotech holdings
Invesco Nasdaq Biotechnology ETF offers a lower expense ratio and a higher trailing dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered a higher 1-year total return and experienced a less severe maximum drawdown than Invesco Nasdaq Biotechnology ETF.
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
Invesco Nasdaq Biotechnology ETF (NASDAQ: IBBQ - Get Free Report) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 23,534 shares, an increase of 202.1% from the December 31st total of 7,789 shares. Approximately 0.9% of the shares of the stock are short sold.
The Fed lifted market confidence amid economic uncertainty, leading to a rally in the U.S. stock market.
IBBQ is a relatively new U.S. biotech ETF that competes with established peers like IBB and XBI. IBBQ has outperformed both since its June 2021 launch date. However, there are specific risks investors should consider first. In addition to the volatile nature of the biotech industry, I'll review IBBQ's liquidity, concentration, and quality features in detail. IBBQ also has a high liquidation risk. With only $38 million in assets under management and a 0.19% expense ratio, IBBQ likely isn't a profitable product for Invesco.
Following a multiyear run of disappointment, biotech stocks and related ETFs are showing signs of life. For the past 90 days ending February 29, the widely observed Nasdaq Biotechnology Index was higher by almost 17%.